Results 181 to 190 of about 62,672 (281)

Ivermectin Toxicity in Humans and Animals: Clinical Spectrum, Mechanisms, and Management

Journal of Applied Toxicology, Volume 46, Issue 6, Page 1856-1870, June 2026.
ABSTRACT Ivermectin is a widely used macrocyclic lactone with established efficacy against a broad range of parasitic infections in humans and animals and a long‐standing reputation for clinical safety. However, increasing evidence indicates that ivermectin can produce clinically relevant toxicity under specific conditions, particularly involving the ...
Serkan Yilmaz, Bayram Göktaş, İlker Ateş, Mustafa Çelik   +3 more
wiley   +1 more source

Trends and Patterns of Adverse Drug Reaction Reporting in Sierra Leone: A Retrospective Analysis of VigiFlow Data (2008-2022). [PDF]

Pharmacoepidemiol Drug Saf
Jalloh I, Abiri OT, James PB, Vagiri R, Padayachee N.   +4 more
europepmc   +1 more source

Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database. [PDF]

Curr Ther Res Clin Exp
Susini D, Crea R, Morabito P, Kleyn A, Bizzarri A.   +4 more
europepmc   +1 more source

Magnitude, Preventability, and Determinants of Adverse Drug Reactions Among Hospitalized Obstetric Patients in Ethiopia: A Prospective Observational Study

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Adverse drug reactions (ADRs) are an important and potentially preventable cause of morbidity among hospitalized obstetric patients, with implications for both maternal and fetal safety, yet evidence from low‐resource settings remains limited.
Getachew Yitayew Tarekegn, Endalemaw Tsegaw, Fisseha Nigussie Dagnew, Sisay Sitotaw Anberbr, Tilaye Arega Moges, Samuel Berihun Dagnew, Samuel Agegnew Wondm, Tigabu Eskeziya Zerihun, Abel Temeche Kassaw, Desalegn Addis Mussie   +9 more
wiley   +1 more source

Artificial intelligence in pharmacovigilance: toward real-time, explainable, and global drug-safety systems. [PDF]

Ann Med Surg (Lond)
Ali U, Batool ST, Mahato RK.
europepmc   +1 more source

Age‐Dependent Differences in Canakinumab Safety: A Comprehensive Pharmacovigilance Analysis Using the FAERS Database

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Youyang Wang, Ngasin Lam, Xiaoming Huang, Yang Jiao   +3 more
wiley   +1 more source

Sex-specific adverse event profiles of PDE4 inhibitors: a comparative big-data pharmacovigilance study of apremilast, crisaborole, and roflumilast in FAERS (2004-2025). [PDF]

Front Pharmacol
Huang B, Gu S, Wang S, Ma Y, Zhou Y, Wang W.   +5 more
europepmc   +1 more source

The Antipsychotic Aripiprazole Induces Cytotoxicity in Bladder Cancer Cells While Preserving Urothelial and Bladder Function

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
Current bladder cancer therapies can cause toxicity and bladder dysfunction. Brief intravesical‐like aripiprazole exposure reduced bladder cancer cell viability and was associated with redox stress and caspase‐3 activation, while ex vivo findings suggested preserved bladder structure and function, warranting further investigation as a potential ...
Liam A. O'Callaghan, Katie Powell, Russ Chess‐Williams, Catherine McDermott   +3 more
wiley   +1 more source

Computational modelling and network medicine in drug toxicology and clinical pharmacovigilance. [PDF]

J Transl Med
Zhao Q, Li X, Balan V.
europepmc   +1 more source

Epicutaneous and Drug Provocation Testing in Severe Cutaneous Adverse Reactions: A 20‐Year Single‐Centre Experience

Contact Dermatitis, Volume 94, Issue 6, Page 677-688, June 2026.
This study provides reassuring evidence in favour of early skin testing in patients with SCARs, argues against the necessity of a 6‐month delay, and underscores the pivotal role of oral provocation tests in the safe reintroduction of essential therapies. ABSTRACT Background Identifying and discontinuing the offending drug(s) in severe cutaneous adverse
Zohra Chadli, Khadija Mansour, Ghada Jaouahdou, Manel Ben Belgacem, Yosra Soua, Nadia Ben Fredj, Jameleddine Zili, Haifa Ben Romdhane, Karim Aouam   +8 more
wiley   +1 more source